The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo had an early lead on Lilly, with Wegovy reaching market before Lilly’s rival Zepbound and, at least so far, securing broader insurance coverage. But that early advantage may be dissipating.

Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly 'We're no longer a country that cannot be trusted' Dave Ramsey warns Americans on Social Security, Roth IRA ...

Novo Nordisk's (NYSE: NVO ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month ...

Novo Nordisk will offer its weight loss drug Wegovy for less than half of its usual price per month through a new direct-to-consumer online pharmacy. The cash-pay offering is available to millions ...

Novo Nordisk (NYSE: NVO) shareholders know all ... The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community.

South Africa's competition watchdog probes Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market South Africa’s competition watchdog is investigating ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market. South Africa’s Competition ...

March 4 (Reuters) - South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority ...